Cardiovascular Department, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an, Shaanxi, China.
Gut Microbes. 2024 Jan-Dec;16(1):2415487. doi: 10.1080/19490976.2024.2415487. Epub 2024 Oct 29.
Statins, known as HMG-CoA reductase inhibitors, are widely utilized to reduce blood cholesterol levels and possess pleiotropic effects, including the influence on inflammation and macrophage proliferation. Despite their significant impact in diminishing the incidence of cardiovascular events and mortality, individual responses to statin therapy vary considerably. Understanding this variability is essential for optimizing treatment outcomes and minimizing adverse effects. The gut microbiota, a complex ecosystem of microorganisms within the gastrointestinal tract, plays a critical role in human health and disease. Emerging evidence has linked the gut microbiota to drug metabolism and response, with the potential to modulate the efficacy of statin therapy and its side effects. This review provides a comprehensive overview of the interaction between the gut microbiota and statins. It discusses how the gut microbiota can influence the therapeutic effects and side effects of statins and examines the mechanisms by which the gut microbiota affect statin response and cardiovascular diseases.
他汀类药物,又称 HMG-CoA 还原酶抑制剂,被广泛用于降低血液胆固醇水平,具有多种作用,包括对炎症和巨噬细胞增殖的影响。尽管他汀类药物治疗在降低心血管事件和死亡率方面具有显著效果,但个体对其治疗的反应差异很大。了解这种变异性对于优化治疗效果和最小化不良反应至关重要。肠道微生物群是胃肠道内微生物的复杂生态系统,在人类健康和疾病中起着关键作用。新出现的证据将肠道微生物群与药物代谢和反应联系起来,有可能调节他汀类药物治疗的疗效及其副作用。这篇综述全面概述了肠道微生物群与他汀类药物之间的相互作用。它讨论了肠道微生物群如何影响他汀类药物的治疗效果和副作用,并研究了肠道微生物群影响他汀类药物反应和心血管疾病的机制。